MagForce NT GmbH
MagForce NT GmbH (Nanotherm Therapeutics) is a pre-revenue medical device company developing Nanotherm®AS1 nanoparticles and the NanoActivator™ RF system for contactless, image-guided thermal ablation of solid tumors, targeting oncology departments and clinical research centers.
- Company typePrivate
- Founded1997
- HeadquartersBerlin, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What MagForce NT GmbH does
MagForce NT GmbH (operating commercially as Nanotherm Therapeutics) is a medical device company developing nanotechnology-based thermal ablation therapies for solid tumors. Its core platform consists of two integrated components: Nanotherm®AS1, bioengineered non-toxic nanoparticles delivered directly into tumor tissue via a universal 19G needle, and the NanoActivator™, an RF energy device that generates a contactless alternating magnetic field to heat the nanoparticles and produce a predictable, controlled ablation zone. The company's proprietary 2-step image-guided workflow — Deliver, Confirm, Predict, Activate, Ablate — uses standard imaging (CT, EBUS, CBCT) to visualize nanoparticle deposits before activation, allowing the ablation zone to be defined in advance and reducing collateral damage to adjacent healthy tissue. The contactless energy delivery is designed to be insensitive to patient motion (breathing and heartbeat), addressing a key limitation of conventional antenna-based ablation methods.
The company has accumulated more than 25 years of research and development, supported by over 100 patents globally, ISO 13485:2016 quality certification, and clinical experience in 200+ patients with over 1,000 activations across 3 active clinical research centers. It operates through a Delaware-incorporated U.S. entity (Nanotherm Therapeutics Inc., Wilmington, DE) and a German operating entity (Nanotherm Therapeutics GmbH, Berlin). Financing to date has come from a mix of equity and debt instruments, including a $15 million round led by Heliad AG and Mithril Capital Management in 2014, a $5.66 million round led by Apeiron Investment Group in 2020, and up to EUR 3.5 million in senior bearer notes issued to Lansdowne Investment Company Cyprus Limited in 2022.
Commercially, MagForce NT GmbH is pre-revenue: the Nanotherm system is an investigational device and is not approved for commercial clinical use in any jurisdiction, and prior CE marking in the European Union has been discontinued. The company engages the market through a consultative, demo-driven GTM motion targeting oncology and interventional-radiology departments at clinical research centers, with the strategic intent of progressing regulatory milestones toward eventual commercial authorization. Leadership includes CEO Ben J. Lipps, COO Hoda Tawfik, and Safety Officer & Risk Manager Eva Steier.
MagForce NT GmbH firmographics
Firmographics- Name
- MagForce NT GmbH
- Legal name
- Nanotherm Therapeutics Inc.
- Website
- https://magforce.de
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MagForce NT GmbH (Nanotherm Therapeutics) is a pre-revenue medical device company developing Nanotherm®AS1 nanoparticles and the NanoActivator™ RF system for contactless, image-guided thermal ablation of solid tumors, targeting oncology departments and clinical research centers.
- Ownership category
- akta.pro rank
MagForce NT GmbH industry classification
Industry- Product category
- Nanoparticle Thermal Ablation Systems
- NAICS
- Research and Development in Nanotechnology (541713), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)
- akta.pro secondary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where MagForce NT GmbH is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
MagForce NT GmbH business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Commercialization (Future): As the Nanotherm system is an investigational device not yet approved for commercial clinical use in any jurisdiction, the company is currently pre-revenue. Future revenue is expected to come from sale or licensing of the Nanotherm system (NanoActivator device and AS1 nanoparticles) to clinical treatment centers.
- Technology Licensing (Future): Potential revenue from licensing the proprietary nanoparticle technology and ablation methodology to medical device partners or healthcare institutions. The company holds over 100 patents across key global markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Investigational/Clinical Use Only |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
MagForce NT GmbH product offering
Product offeringCore offering
MagForce NT GmbH (operating as Nanotherm Therapeutics) develops and manufactures a nanoparticle-based thermal ablation system for the treatment of solid tumors. The platform consists of Nanotherm®AS1 bioengineered nanoparticles injected directly into tumor tissue and the NanoActivator™ RF energy device that generates a contactless alternating magnetic field to heat the nanoparticles and ablate the tumor within a predictable zone. The technology is currently investigational and not approved for commercial clinical use in any jurisdiction.
Product overview
Nanotherm Therapeutics (MagForce NT GmbH) offers a unified thermal ablation platform consisting of two integrated components: the Nanotherm®AS1 bioengineered nanoparticles delivered directly into tumor tissue via a universal 19G needle, and the NanoActivator™ device that generates an alternating magnetic field to heat the nanoparticles and ablate target tissue within a predictable, controlled zone. The platform uses a 2-step image-guided therapy workflow (Deliver-Confirm-Predict-Activate-Ablate) to achieve targeted thermal ablation of solid tumors with reduced collateral damage to adjacent structures.
Differentiator
Problem solved
Functional benefit
Brands
- Nanotherm®AS1: Bioengineered non-toxic nanoparticles placed into tumor tissue that remain in place due to their coating for targeted thermal ablation.
- NanoActivator™
Products and services
- Nanotherm®AS1
Quantifiable outcome
- 200+ patients treated with over 1000 activations demonstrating clinical safety and efficacy
- +2 more outcomes
Companies that use MagForce NT GmbH
Customer profileSegments2 records
Ideal customer profiles2 records
MagForce NT GmbH technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
MagForce NT GmbH partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights4 records
MagForce NT GmbH competitors and assessment
Company assessmentEmerging players
- Monteris Medical: Maker of NeuroBlate, a minimally invasive laser interstitial thermal therapy (LITT) system for brain tumors; relevant analogue given MagForce's historical brain tumor (glioblastoma) research focus.
- EDAP TMS: Developer of Focal One HIFU platform for prostate cancer ablation—competes directly in the prostate indication using a different energy modality (high-intensity focused ultrasound).
- InSightec: Pioneer in MR-guided focused ultrasound (MRgFUS) for non-invasive tissue ablation; shares Nanotherm's image-guided, motion-management narrative across oncology and other indications.
- Nanobiotix: Clinical-stage nanomedicine company developing NBTXR3 radioenhancer nanoparticles for solid tumors; comparable as a nanoparticle-platform oncology company pursuing novel mechanism approaches.
Broad incumbents
- Medtronic: Dominant incumbent in RF ablation (Cool-tip) and microwave ablation (Emprint) across multiple oncology indications; represents the entrenched standard of care that Nanotherm must displace.
- AngioDynamics: Offers NanoKnife (irreversible electroporation) alongside RF and microwave ablation products—a relevant competitor in soft tissue ablation with a similarly novel mechanism story to Nanotherm.
- Boston Scientific: Major medtech with broad RF/microwave ablation portfolio and interventional oncology presence; competes for the same hospital procurement budgets and interventional radiology workflow slots.
- Johnson & Johnson (Ethicon / NeuWave): Ethicon's NeuWave microwave ablation system and broader interventional oncology portfolio represent a well-funded incumbent competitor in solid tumor ablation.
Direct peers
- Profound Medical: Commercial-stage TULSA-PRO system uses transurethral MR-guided ultrasound for prostate tissue ablation—a competing minimally-invasive thermal ablation modality in the same primary indication (prostate cancer).
- Nanospectra Biosciences: Developer of AuroLase, a gold nanoshell-mediated photothermal ablation therapy for prostate cancer—the closest direct analogue to MagForce's nanoparticle thermal ablation approach in both modality and indication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MagForce NT GmbH social profiles
Digital presenceMagForce NT GmbH compliance and trust
Trust signalCompliance1 record
MagForce NT GmbH financial estimates
Financial estimateRevenue estimate
Valuation estimate
MagForce NT GmbH leadership team
Management profileNumber of profiles
Profiles3 records
MagForce NT GmbH funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MagForce NT GmbH M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MagForce NT GmbH
What does MagForce NT GmbH do?
MagForce NT GmbH (operating as Nanotherm Therapeutics) develops and manufactures a nanoparticle-based thermal ablation system for the treatment of solid tumors. The platform consists of Nanotherm®AS1 bioengineered nanoparticles injected directly into tumor tissue and the NanoActivator™ RF energy device that generates a contactless alternating magnetic field to heat the nanoparticles and ablate the tumor within a predictable zone. The technology is currently investigational and not approved for commercial clinical use in any jurisdiction.
Is MagForce NT GmbH a public or private company?
MagForce NT GmbH is a private company. It is classified as public and is currently operating.
When was MagForce NT GmbH founded?
MagForce NT GmbH was founded in 1997. It employs 51 to 100 people.
Where is MagForce NT GmbH based?
MagForce NT GmbH is headquartered in Berlin, Germany, in the Europe region.
How does MagForce NT GmbH make money?
Two revenue lines are on record. Medical Device Commercialization (Future) is the primary driver. The others are technology Licensing (Future).
Who are MagForce NT GmbH's main competitors?
Emerging players on record are Monteris Medical, EDAP TMS, InSightec and Nanobiotix. Broad incumbents are Medtronic, AngioDynamics, Boston Scientific and Johnson & Johnson (Ethicon / NeuWave). Direct peers are Profound Medical and Nanospectra Biosciences.
Does MagForce NT GmbH have an API?
No public API is recorded for MagForce NT GmbH.
What industry is MagForce NT GmbH in?
MagForce NT GmbH's product category is Nanoparticle Thermal Ablation Systems. Its primary akta.pro industry code is HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 541713 and its SIC code is 3845.